<DOC>
	<DOCNO>NCT00002079</DOCNO>
	<brief_summary>To assess dose-related antiviral effect SC-48334 zidovudine ( AZT ) administer combination individually HIV-1 positive patient 200 - 500 CD4+ cells/mm3 . To determine safety escalate dos SC-48334 administer combination three dose AZT symptomatic HIV-1 positive patient 200 - 500 CD4+ cells/mm3 , assess pharmacokinetics two drug , give separately combination .</brief_summary>
	<brief_title>Phase II Study Safety Surrogate Marker Efficacy Butyldeoxynojirimycin ( SC-48334 ) AZT Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3 . ( NOTE : Asymptomatic HIV-1 Infected Patients Also Eligible )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 cell count 200 500 cells/mm3 . Prior therapy 12 48 week AZT . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Clinically significant diarrhea without definable cause ( &gt; 3 liquid stool per day 7 day within 6 month prior study entry ) . Diarrhea , , know nonHIVrelated cause occur within 1 month prior study entry . Symptoms meeting CDC criterion AIDS classification . Fever constitutional sign HIV disease ( &gt; 38.5 degree C persist 14 consecutive day 15 day give 30day period prior study entry ) . Malignancies , basal cell carcinoma Kaposi 's sarcoma ( provide patient few 10 Kaposi 's sarcoma lesion , nonskin lesion , requirement systemic treatment ) . Significant organ dysfunction . Known hypersensitivity SC48334 AZT related compound . Concurrent Medication : Excluded : Any investigational drug SC48334 . Any antiHIV drug AZT . Cancer chemotherapy . Patients follow prior condition exclude : History cataract know increased risk cataract formation . Known hypersensitivity SC48334 AZT related compound . History lactose intolerance . Prior Medication : Excluded : Prior SC48334 . Cancer chemotherapy within 6 month prior study entry . Treatment investigational drug drug antiHIV activity , AZT , within 30 day prior study entry . Prior Treatment : Excluded : Wholebody irradiation within 6 month prior study entry . Current use illicit substance , abuse alcohol , would limit compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1993</verification_date>
	<keyword>Zidovudine</keyword>
	<keyword>1-Deoxynojirimycin</keyword>
</DOC>